Current Allergy and Asthma Reports

, Volume 8, Issue 2, pp 102–110 | Cite as

Sublingual immunotherapy and allergic rhinitis



This paper reviews the safety and efficacy of sublingual immunotherapy (SLIT) in the treatment of allergic rhinitis. The literature from 1986 through 2007 shows approximately a 6000-fold range in doses found to be effective with SLIT. However, recent studies in large patient populations have demonstrated a clear dose response with an effective dose range that appears to be equivalent to one to two times the monthly subcutaneous immunotherapy dose administered daily or weekly (ie, 15 to 30 μg of major allergen). Further study is needed to establish the optimal dose and dosing schedule for each formulation. Local reactions (eg, oral itchiness) are common, and serious adverse reactions, although rare, have been reported. Cost-effective analysis cannot be made until the effective dose is established. SLIT appears to be a promising treatment for allergic rhinitis, but it is currently considered investigational in the United States until a formulation approved by the US Food and Drug Administration is available.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Durham SR, Walker SM, Varga EM, et al.: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468–475.PubMedCrossRefGoogle Scholar
  2. 2.
    Eng PA, Borer-Reinhold M, Heijnen IA, et al.: Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006, 61:198–201.PubMedCrossRefGoogle Scholar
  3. 3.
    Purello-D’Ambrosio F, Gangemi S, Merendino RA, et al.: Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001, 31:1295–1302.PubMedCrossRefGoogle Scholar
  4. 4.
    Polosa R, Al-Delaimy WK, Russo C, et al.: Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res 2005, 6:153.PubMedCrossRefGoogle Scholar
  5. 5.
    Des Roches A, Paradis L, Menardo JL, et al.: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997, 99:450–453.PubMedCrossRefGoogle Scholar
  6. 6.
    Jacobsen L, Niggemann B, Dreborg S, et al.: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007, 62:943–948.PubMedCrossRefGoogle Scholar
  7. 7.
    Bernstein JA: Pharmacoeconomic considerations for allergen immunotherapy. Clin Allergy Immunol 2004, 18:151–164.PubMedGoogle Scholar
  8. 8.
    Ariano R, Berto P, Tracci D, et al.: Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 2006, 27:159–163.PubMedGoogle Scholar
  9. 9.
    Hankin CS, Cox L, Wang Z, et al.: Allergy immunotherapy practice patterns and associated outcomes of care. J Allergy Clin Immunol 2007, 199:S159.CrossRefGoogle Scholar
  10. 10.
    Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group [no authors listed]. N Engl J Med 2000, 343:1054–1063.Google Scholar
  11. 11.
    Guilbert TW, Morgan WJ, Zeiger RS, et al.: Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006, 354:1985–1997.PubMedCrossRefGoogle Scholar
  12. 12.
    Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology: Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007, 120:S25–S85.CrossRefGoogle Scholar
  13. 13.
    Cox LS, Linnemann DL, Nolte H, et al.: Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006, 117:1021–1035.PubMedCrossRefGoogle Scholar
  14. 14.
    Alvarez-Cuesta E, Berges-Gimeno P, Gonzalez-Mancebo E, et al.: Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study. Allergy 2007, 62:810–817. [Published erratum appears in Allergy 2007, 62:1100.]PubMedCrossRefGoogle Scholar
  15. 15.
    Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A: A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993, 92:229–236.PubMedCrossRefGoogle Scholar
  16. 16.
    Didier A, Malling HJ, Worm M, et al.: Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 120:1338–1345.PubMedCrossRefGoogle Scholar
  17. 17.
    Durham S, Yang W, Pedersen M, et al.: Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:802–809.PubMedCrossRefGoogle Scholar
  18. 18.
    Dahl R, Kapp A, Colombo G, et al.: Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 118:434–440.PubMedCrossRefGoogle Scholar
  19. 19.
    Dahl, R, Stender A, Rak S: Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006, 61:185–190.PubMedCrossRefGoogle Scholar
  20. 20.
    Durham SR, Riis B: Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 2007, 62:954–957.PubMedCrossRefGoogle Scholar
  21. 21.
    Dahl R, Kapp A, Colombo G, et al.: Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2007, Epub ahead of print.Google Scholar
  22. 22.
    Frew AJ, Powell RJ, Corrigan CJ, et al.: Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:319–325.PubMedCrossRefGoogle Scholar
  23. 23.
    Valovirta E, Jacobsen L, Ljorring C, et al.: Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006, 61:1177–1183.PubMedCrossRefGoogle Scholar
  24. 24.
    Savolainen J, Jacobsen L, Valovirta E: Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006, 61:1184–1190.PubMedCrossRefGoogle Scholar
  25. 25.
    Arbes SJ, Jr, Gergen PJ, Elliott L, et al.: Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005, 116:377–383.PubMedCrossRefGoogle Scholar
  26. 26.
    Marogna M, Spadolini I, Massolo A, et al.: Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol 2007, 98:274–280.PubMedGoogle Scholar
  27. 27.
    Khinchi MS, Poulsen LK, Carat F, et al.: Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004, 59:45–53.PubMedCrossRefGoogle Scholar
  28. 28.
    Wilson DR, Torres LI, Durham SR: Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003, 2:CD002893.Google Scholar
  29. 29.
    Calderon MA, Alves B, Jacobson M, et al.: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, 1:CD001936.Google Scholar
  30. 30.
    Polosa R, Li Gotti F, Mangano G, et al.: Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy 2004, 59:1224–1228.PubMedCrossRefGoogle Scholar
  31. 31.
    Di Rienzo V, Marcucci F, Puccinelli P, et al.: Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003, 33:206–210.PubMedCrossRefGoogle Scholar
  32. 32.
    Novembre E, Galli E, Landi F, et al.: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004, 114:851–857.PubMedCrossRefGoogle Scholar
  33. 33.
    Des Roches A, Paradis L, Knani J, et al.: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996, 51:430–433.PubMedCrossRefGoogle Scholar
  34. 34.
    Cox L, Cohn JR: Duration of allergen immunotherapy in respiratory allergy: when is enough, enough? Ann Allergy Asthma Immunol 2007, 98:416–426.PubMedGoogle Scholar
  35. 35.
    Marogna M, Bruno M, Massolo A, et al.: Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: a long-term (13-year) retrospective study in real life. Int Arch Allergy Immunol 2007, 142:70–78.PubMedCrossRefGoogle Scholar
  36. 36.
    Tari MG, Mancino M, Monti G: Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990, 18:277–284.Google Scholar
  37. 37.
    Rolinck-Werninghaus C, Wolf H, Liebke C, et al.: A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004, 59:1285–1293.PubMedCrossRefGoogle Scholar
  38. 38.
    Stewart GE 2nd, Lockey RF: Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992, 90(4 Pt 1):567–578.PubMedCrossRefGoogle Scholar
  39. 39.
    Van Metre TE, Adkinson NF, Amodio FJ, et al.: A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982, 69:181–193.PubMedCrossRefGoogle Scholar
  40. 40.
    Amin HS, Liss GM, Bernstein DI: Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006, 117:169–175.PubMedCrossRefGoogle Scholar
  41. 41.
    Bernstein DI, Wanner M, Borish L, et al.: Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol 2004, 113:1129–1136.PubMedCrossRefGoogle Scholar
  42. 42.
    Reid MJ, Lockey RF, Turkeltaub PC, et al.: Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol 1993, 92(1 Pt 1):6–15.PubMedCrossRefGoogle Scholar
  43. 43.
    Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC: Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987, 79:660–677.PubMedCrossRefGoogle Scholar
  44. 44.
    Antico A, Pagani M, Crema A: Anaphylaxis by latex sublingual immunotherapy. Allergy 2006, 61:1236–1237.PubMedCrossRefGoogle Scholar
  45. 45.
    Eifan AO, Keles S, Bahceciler NN, et al.: Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007, 62:567–568.PubMedCrossRefGoogle Scholar
  46. 46.
    Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA: Anaphylaxis to sublingual immunotherapy. Allergy 2006, 61:1235.PubMedCrossRefGoogle Scholar
  47. 47.
    Bachert C, Vestenbaek U, Christensen J, et al.: Cost-effectiveness of grass allergen tablet (GRAZAX(R)) for the prevention of seasonal grass pollen induced rhinoconjunctivitis: a Northern European perspective. Clin Exp Allergy 2007, 37:772–779.PubMedCrossRefGoogle Scholar
  48. 48.
    Andre C, Perrin-Fayolle M, Grosclaude M, et al.: A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003, 131:111–118.PubMedCrossRefGoogle Scholar
  49. 49.
    Marcucci F, Sensi L, Di Cara G, et al.: Dose dependence of immunological response to sublingual immunotherapy. Allergy 2005, 60:952–956.PubMedCrossRefGoogle Scholar
  50. 50.
    Bordignon V, Burastero SE: Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 2006, 97:158–163.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Nova Southeastern University Osteopathic College of MedicineFort LauderdaleUSA

Personalised recommendations